Hot Features
ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical ... ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial for the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100 a humanized monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of numerous inflammatory diseases, with cardiometabolic conditions associated with obesity as the lead. The company has a license agreement with L&F Research LLC, and InflamaCORE, LLC. ZyVersa Therapeutics, Inc. was founded in 2014 and is based in Weston, Florida. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.00545 | -3.11606632361 | 0.1749 | 0.1999 | 0.161 | 11460 | 0.19056763 | CS |
| 4 | -0.03325 | -16.4035520474 | 0.2027 | 0.2139 | 0.161 | 7722 | 0.18946442 | CS |
| 12 | -0.05055 | -22.9772727273 | 0.22 | 0.2367 | 0.16 | 10579 | 0.1983462 | CS |
| 26 | 0.03615 | 27.11927982 | 0.1333 | 0.3 | 0.1257 | 43446 | 0.21151636 | CS |
| 52 | 0.01485 | 9.60543337646 | 0.1546 | 0.3113 | 0.11 | 61892 | 0.18715615 | CS |
| 156 | 0.01485 | 9.60543337646 | 0.1546 | 0.3113 | 0.11 | 61892 | 0.18715615 | CS |
| 260 | 0.01485 | 9.60543337646 | 0.1546 | 0.3113 | 0.11 | 61892 | 0.18715615 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.